Congress of the International Society on Thrombosis and Haemostasis

Back

Prevalence, characteristics and mortality rates of individuals eligible for lipid lowering using the JUPITER criteria in a general population sample

Abstract number: OC-WE-103

Cushman¹ M., McClure² L.A., Lakoski³ S.G., Jenny⁴ N.S.

¹¹Department of Medicine, University of Vermont, Colchester ²²Department of Biostatistics, University of Alabama at Birmingham, Birmingham ³³Department of Medicine, University of Texas Southwestern, Dallas ⁴⁴Department of Pathology, University of Vermont, Colchester, VT, USA

How-to-cite Cushman M, McClure LA, Lakoski SG, Jenny NS. Prevalence, characteristics and mortality rates of individuals eligible for lipid lowering using the JUPITER criteria in a general population sample. Journal of Thrombosis and Haemostasis 2009; Volume 7, Supplement 2: Abstract OC-WE-103

Background: The Justification of the Use of Statins in Primary Prevention: an Intervention Trial Using Rosuvastatin (JUPITER) trial recently reported reduction of cardiovascular and all cause mortality with statin treatment in patients with elevated C-reactive protein concentration who were not eligible for lipid-lowering treatment based on existing guidelines. We evaluated the impact of JUPITER entry criteria in a general population sample and determined mortality rates in those eligible or not eligible for statin treatment based on these criteria.

Methods: Participants were 11 339 participants of the REasons for Geographic And Racial Differences in Stroke (REGARDS) observational study cohort who were American men > 50, women > 65 years old without vascular diagnoses and not using lipid-lowering treatment at a baseline examination in their homes between 2003–2007.

Results: Among 11 339 participants, 21% (2342) met JUPITER entry criteria. Compared to JUPITER participants, these participants were more often women, black and had metabolic syndrome and used aspirin for cardioprotection. Over a median of 3.5 years follow-up, the mortality rate among REGARDS participants eligible for JUPITER was 1.17 per 100 person-years (95% CI 0.94–1.42). Compared to those otherwise eligible who had C-reactive protein < 2 mg/L (n = 2,620), those with C-reactive protein ≥ 2 mg/L (eg. trial eligible) had a multivariable-adjusted relative risk of 1.5 (95% CI, 1.1–2.2) for total mortality.

Conclusions: Among these men and women without cardiovascular disease, 21% would be newly eligible for lipid-lowering treatment based on JUPITER trial eligibility. Observed mortality rates suggest that if these criteria were used to prescribe lipid-lowering, there would be 2.3 fewer deaths per 1000 treated persons.

Disclosure of interest: none declared.

To cite this abstract use the following format:

Journal of Thrombosis and Haemostasis 2007; Volume 5, Supplement 2: abstract number

Session Details

Date:	Unpresented
Time:	N/A
Session name:	ISTH2009
Subject:
Location:
Presentation type:
Back to top